HeartFlow took a $90 million step toward the $150 million it hopes to raise in a Series E round for the cardiac imaging technology it’s marketing.
Redwood City, Calif.-based HeartFlow’s FFRct technology works by taking the data from a standard CT scan and applying algorithms that result in a color-coded 3D “map” detailing the changes in flow across coronary lesions.
Last week reports surfaced that the company was eyeing a $150 million raise, which would vault it into “unicorn” territory with a $1.4 billion valuation. HeartFlow’s $99.9 million Series D valued the company at $760 million in May 2016.
In a Nov. 30 regulatory filing released yesterday, HeartFlow reported raising $90.0 million from a pair of unnamed investors in an equity round launched Nov. 20.
Earlier this month the company won a new technology ambulatory payment classification from the Centers for Medicare & Medicaid Services.
In late August, HeartFlow said it won positive medical policies for its HeartFlow FFRct fractional flow reserve analysis system from three separate Blue Cross Blue Shield providers.
